This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Mylan, Aurobindo denied judgment against US states' antitrust claims over generic drugs

( February 18, 2026, 23:31 GMT | Official Statement) -- MLex Summary: Mylan and Aurobindo Pharma were denied reconsideration on summary judgments against states’ antitrust claims over generic drugs. US District Judge Michael P. Shea said the states are not, as sovereign enforcers, required to show antitrust injury to prove a violation of their own antitrust laws that would allow them to collect civil penalties. Docket entry follows below:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections